Singapore Technologies Engineering Ltd (SGX:S63)

Verve Therapeutics Ratios and Metrics

Market cap in millions SGD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 7, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	27,780	14,514	12,116	10,428	11,707	11,901
Market Cap Growth	19.80%	19.80%	16.18%	-10.93%	-1.63%	-3.05%
Enterprise Value	33,457	20,508	18,170	16,296	13,421	13,630
Last Close Price	8.90	4.60	3.70	3.06	3.24	3.17
PE Ratio	39.82	20.67	20.66	19.49	20.52	22.81
Forward PE	33.28	18.66	18.22	17.34	20.19	22.81
PS Ratio	2.46	1.29	1.20	1.15	1.52	1.66
PB Ratio	9.41	4.92	4.40	3.93	4.39	4.62
P/TBV Ratio	-	-	-	-	12.50	14.55
P/FCF Ratio	22.45	11.73	18.98	-	14.59	8.93
P/OCF Ratio	16.17	8.45	10.28	15.49	10.51	7.76
PEG Ratio	2.50	1.24	1.19	3.40	3.48	10.86
EV/Sales Ratio	2.97	1.82	1.80	1.80	1.75	1.90
EV/EBITDA Ratio	21.24	14.56	14.55	15.59	14.34	15.20
EV/EBIT Ratio	30.71	20.14	20.88	24.48	20.67	21.95
EV/FCF Ratio	27.03	16.57	28.47	-	16.73	10.23
Debt / Equity Ratio	1.97	1.97	2.22	2.47	0.80	0.80
Debt / EBITDA Ratio	3.87	3.87	4.57	5.80	2.10	2.12
Debt / FCF Ratio	4.71	4.71	9.58	-	2.65	1.55
Asset Turnover	0.71	0.71	0.67	0.71	0.75	0.74
Inventory Turnover	4.60	4.60	4.54	4.98	4.87	4.34
Quick Ratio	0.55	0.55	0.58	0.50	0.80	0.79
Current Ratio	0.89	0.89	0.91	0.77	1.15	1.16
Return on Equity (ROE)	25.57%	25.57%	22.36%	20.42%	21.63%	20.75%
Return on Assets (ROA)	4.03%	4.03%	3.58%	3.27%	3.96%	3.98%
Return on Capital (ROIC)	7.22%	7.22%	6.02%	5.95%	8.61%	8.16%
Return on Capital Employed (ROCE)	12.80%	12.80%	10.80%	9.60%	11.10%	10.90%
Earnings Yield	2.53%	4.84%	4.84%	5.13%	4.87%	4.38%
FCF Yield	4.45%	8.53%	5.27%	-0.86%	6.85%	11.20%
Dividend Yield	2.25%	3.69%	4.32%	5.24%	4.63%	4.73%
Payout Ratio	71.04%	71.04%	85.03%	128.15%	82.01%	89.69%
Buyback Yield / Dilution	-0.12%	-0.12%	-0.09%	0.01%	0.02%	0.05%
Total Shareholder Return	2.13%	3.57%	4.23%	5.24%	4.65%	4.78%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.